This Week in Virology TWiV 1267: A cancer vaccine and an mpox treatment
Nov 2, 2025
Exploring the potential of Gardasil-9 for HPV-positive women, the discussion reveals its efficacy in reducing persistent virus and lesion progression. The hosts also dive into groundbreaking research on human monoclonal antibodies against the monkeypox virus, highlighting their role in protecting against lethal diseases. In lighter moments, they touch on fascinating topics like civet coffee chemistry and the thoughtful integration of humanism in medicine.
AI Snips
Chapters
Transcript
Episode notes
Gardasil-9 Shows Therapeutic Benefit
- Meta-analysis suggests Gardasil-9 vaccination in HPV-positive adult women reduces persistent infection and progression of precancerous lesions.
- Earlier vaccination around surgical treatment shows the largest benefit and fewer recurrences after excision.
VLP Vaccine Triggers Durable Antibodies
- Gardasil-9 is a virus-like-particle protein vaccine that induces strong, long-lasting antibody responses.
- The vaccine prevents infection and thereby prevents HPV-driven cancers like cervical carcinoma.
Offer Vaccine Around Excisional Procedures
- Offer nine-valent HPV vaccine to adult women with HPV or confirmed SIL, especially before excisional procedures.
- Strengthen evidence with prospective randomized multicenter trials to guide consistent recommendations.